Haemonetics Corporation (HAE) financial statements and ratios from SEC XBRL: revenue $1.33B (TTM), net margin 7.3%, revenue growth -2.0% YoY, P/E 32.2. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.33B |
| Net Margin | 7.3% |
| Revenue Growth (YoY) | -2.0% |
| EPS Growth (YoY) | -38.1% |
| FCF Growth (YoY) | 82.8% |
| P/E Ratio | 32.2 |
| EV / EBITDA | 16.6 |
| Price / Book | 5.78 |
| Price / Sales | 3.65 |
| FCF Yield | 8.0% |
| DCF Value (model) | $4.07 |
| DCF Upside vs Price | -96.2% |
| Altman Z-Score | 3.03 (safe) |
| Piotroski F-Score | 7/9 |
| Sector P/E (Healthcare) | 21.6 |
HAE overview · HAE earnings · HAE KPIs · HAE investor relations · HAE ownership · HAE peers · HAE filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.